The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation. (2017)

Peer-Reviewed Study · Kristin Blom; Wojciech Senkowski; Malin Jarvius et al. · August 2017

Kristin Blom et al., 2017-08: Blom et al. use Connectivity Map signatures and THP-1 cells to argue that mebendazole's anticancer effect may run through M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome signalling.

The MBZ-induced gene expression signature in the promyeloblastic HL-60 cell line was strongly enriched in genes involved in monocyte/macrophage pro-inflammatory (M1) activation.

Kristin Blom et al., 2017-08: Blom et al. use Connectivity Map signatures and THP-1 cells to argue that mebendazole's anticancer effect may run through M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome signalling. Study type: cell lines (HL-60, THP-1) with gene-expression and cytokine assays. N: not applicable. Country: Sweden (Uppsala University). Dose: 'high' and 'low' MBZ concentrations, values not stated in the abstract text captured. Funder: not stated in the abstract; the companion paper states academic grants only. Declared conflicts: no COI field in this record; the same group's 2018 and 2019 papers declare Repos Pharma AB shareholdings (R.L., P.N., M.F.). Comparator: LPS co-treatment and untreated controls. This is the lead named in the prompt as 'Blom K et al. 2017' and the citation is confirmed. Study type: lab.